Influence of secretory phenotype and preoperative preparation on surgical outcome in pheochromocytoma.

alpha-blockers complications pheochromocytoma surgery

Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 10 11 2020
accepted: 14 12 2020
pubmed: 16 12 2020
medline: 16 12 2020
entrez: 15 12 2020
Statut: ppublish

Résumé

Surgery of pheochromocytomas (PCs) still carries a high risk of haemodynamic complications during the perioperative period. We aimed to evaluate the influence of their secretory phenotype and preoperative alpha-blocker treatment on surgical outcome. A retrospective monocentric study at a tertiary medical centre. In this study, 80 consecutive patients operated by the same team for a PC between 1988 and 2018. Diagnosis was based on typical symptoms and signs in 58 patients, genetic testing in 12 and work-up of an adrenal incidentaloma in 9. It was made during surgery in one patient. A genetic predisposition was found in one-third of index cases (21/62). The majority of the patients (73/79) had a secreting PC; more than 2/3 had an adrenergic phenotype and less than 1/3 a noradrenergic phenotype. The rate of perioperative haemodynamic complications was not influenced by the secretory phenotype, but persistent hypertension after surgery, recurrence and malignancy were more frequently observed in patients with a noradrenergic tumour. Preoperative alpha-blocker treatment was given for ≥ 14 days in 29 patients and, although being more symptomatic at diagnosis, these patients had less haemodynamic complications (3/29 vs 12/51 non-treated patients, P = 0.05). The occurrence of haemodynamic complications during surgery was not significantly affected by the secretory phenotype in our study, but noradrenergic tumours show a worse post-surgical outcome. Our data also provide additional support in favour of a sufficient preoperative alpha-blockade in patients with pheochromocytoma.

Identifiants

pubmed: 33320109
doi: 10.1530/EC-20-0537
pii: EC-20-0537
pmc: PMC7923042
doi:
pii:

Types de publication

Journal Article

Langues

eng

Pagination

92-101

Références

J Clin Endocrinol Metab. 2019 May 1;104(5):1386-1393
pubmed: 30462226
Clin Endocrinol (Oxf). 2017 Feb;86(2):163-167
pubmed: 27696513
Horm Metab Res. 2019 Jul;51(7):458-469
pubmed: 30227459
J Am Coll Surg. 2009 Dec;209(6):727-32
pubmed: 19959041
Acta Anaesthesiol Scand. 2009 Apr;53(4):522-7
pubmed: 19239408
J Clin Endocrinol Metab. 2001 Apr;86(4):1480-6
pubmed: 11297571
Endocr Connect. 2018 Jan;7(1):186-192
pubmed: 29217652
Surg Oncol Clin N Am. 1998 Oct;7(4):765-89
pubmed: 9735133
Lancet. 2005 Aug 20-26;366(9486):665-75
pubmed: 16112304
J Clin Endocrinol Metab. 2010 Feb;95(2):678-85
pubmed: 19965926
Br J Surg. 2020 Jan;107(2):e170-e178
pubmed: 31903598
Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102
pubmed: 17237836
Clin Endocrinol (Oxf). 2017 Mar;86(3):309-314
pubmed: 27864838
Horm Metab Res. 2012 May;44(5):328-33
pubmed: 22328163
J Clin Endocrinol Metab. 2015 Feb;100(2):417-21
pubmed: 25405501
J Surg Oncol. 1994 Nov;57(3):196-200
pubmed: 7967610
World J Surg. 1996 Sep;20(7):762-8; discussion 768
pubmed: 8678948
Eur J Endocrinol. 2016 Oct;175(4):R135-45
pubmed: 27080352
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32222768
BMC Surg. 2016 Jun 08;16(1):41
pubmed: 27278528
J Clin Endocrinol Metab. 2011 Feb;96(2):375-84
pubmed: 21147885
Br J Surg. 2020 Jan;107(2):e102-e108
pubmed: 31903584
Eur J Endocrinol. 2019 Oct;181(4):409-420
pubmed: 31370000
Clin Chem. 2005 Apr;51(4):735-44
pubmed: 15718487
Ann Surg Oncol. 2013 May;20(5):1444-50
pubmed: 23512077
J Urol. 1998 Aug;160(2):330-4
pubmed: 9679871
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597347
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32726444
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101416
pubmed: 32295730
Clin Endocrinol (Oxf). 2020 Sep;93(3):288-295
pubmed: 32410303
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5170-5180
pubmed: 31009053
Endocrinol Metab Clin North Am. 2011 Jun;40(2):295-311, vii
pubmed: 21565668
J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6
pubmed: 15644401
J Clin Endocrinol Metab. 2007 Nov;92(11):4069-79
pubmed: 17989126

Auteurs

Raluca Maria Furnica (RM)

Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Muhammad Muddaththir Dusoruth (MM)

Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Alexandre Persu (A)

Department of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Damien Gruson (D)

Department of Biology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Michel Mourad (M)

Endocrine Surgery, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Dominique Maiter (D)

Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Classifications MeSH